isatuximab isatuximab-irfc (Sarclisa)

Indications

• relapsed/refractory multiple myeloma*

* for use in combination with pomalidomide (Pomalyst) & dexamethasone, in patients whose disease progressed on at least two prior therapies, including both lenalidomide (Revlimid) & a proteasome inhibitor

Mechanism of action

• CD38 inhibitor

More general terms

• antineoplastic monoclonal antibody

Additional terms

• daratumumab (Darzalex)